Ramdial 2002.
| Study characteristics | ||
| Methods | Prospective cohort study | |
| Participants | 14 people living with HIV with disseminated cutaneous histoplasmosis | |
| Interventions | ITRA 200 mg BD (4 participants) AmB 0.5–1 mg/kg/day (7 participants) |
|
| Outcomes | Death Clinical success |
|
| Age | Mean 28 (range 3–41) years | |
| Setting | ZAF | |
| Disease severity | Not stated | |
| Notes | Follow‐up: 32 months Death: 5/14; 3 died before treatment started; 1 died day 1 in ITRA group; 1 died day 2 in AmB group Clinical success: 9/14 Induction: 6/9 ITRA; 3/9 dAmB Maintenance: 7/9 ITRA; 2/9 dAmB |
|
AmB: amphotericin B; ART: antiretroviral therapy; BD: twice daily; CNS: central nervous system; dAmB: deoxycholate amphotericin B; FCN: fluconazole; IRIS: immune reconstitution inflammatory syndrome; ITRA: itraconazole; ITT: intention to treat; lAmB: liposomal amphotericin B; OD: once daily; OI: opportunist infection; PDH: progressive disseminated histoplasmosis; PO2: partial pressure of oxygen; POSA: posaconazole; RCT: randomized controlled trial; RNA: ribonucleic acid; SBP: systolic blood pressure; SD: standard deviation; TB: tuberculosis; VL: viral load; VORI: voriconazole.